Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov 26;43(11):114981.
doi: 10.1016/j.celrep.2024.114981. Epub 2024 Nov 12.

Karyotype evolution in response to chemoradiotherapy and upon recurrence of esophageal adenocarcinomas

Affiliations
Free article

Karyotype evolution in response to chemoradiotherapy and upon recurrence of esophageal adenocarcinomas

Karen van der Sluis et al. Cell Rep. .
Free article

Abstract

The genome of esophageal adenocarcinoma (EAC) is highly unstable and might evolve over time. Here, we track karyotype evolution in EACs in response to treatment and upon recurrence through multi-region and longitudinal analysis. To this end, we introduce L-PAC (low-purity inference of absolute copy-number alterations [CNAs]), a bio-informatics technique that allows inference of absolute CNAs of low-purity samples by leveraging the information of high-purity samples from the same cancer. Quantitative analysis of matched absolute CNAs reveals that the amount of karyotype evolution induced by chemoradiotherapy (CRT) is predictive for early recurrence and depends on the initial level of karyotype intra-tumor heterogeneity. We observe that CNAs acquired in response to CRT are partially reversed back to the initial state upon recurrence. Hence, CRT alters the fitness landscape to which tumors can adjust by adapting their karyotype. Together, our results indicate that karyotype plasticity contributes to the therapy resistance of EACs.

Keywords: CP: Cancer; CP: Genomics; chromosomal instability; esophageal cancer; therapy resistance; tumor evolution.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests B.C. has several patents pending and/or issued not related to this work. P.S. has done unrelated consultancy for MSD and Bayer and received payment from MEDtalks for educational presentation.

References

Publication types

Supplementary concepts

LinkOut - more resources